Nuwellis Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Nuwellis kazanç ve gelirinin sırasıyla yıllık 64% ve 35.8% oranında artması tahmin edilirken, EPS'nin yıllık 82.2% oranında büyümesi bekleniyor.

Anahtar bilgiler

64.0%

Kazanç büyüme oranı

82.2%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.1%
Gelir büyüme oranı	35.8%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	12 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Nuwellis hires Lynn Blake as CFO

Oct 19

Nuwellis surges 90% on positive data from Postoperative Coronary Artery Bypass Grafting treatment

Aug 31

Nuwellis Q2 2022 Earnings Preview

Aug 08

CHF Solutions down 10% on Q3 miss

Nov 10

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:NUWE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	15	-5	N/A	N/A	2
12/31/2025	11	-7	N/A	N/A	2
12/31/2024	9	-10	N/A	N/A	2
9/30/2024	9	-17	-11	-11	N/A
6/30/2024	9	-23	-12	-12	N/A
3/31/2024	9	-20	-15	-15	N/A
12/31/2023	9	-23	-18	-18	N/A
9/30/2023	9	-17	-19	-18	N/A
6/30/2023	8	-17	-18	-18	N/A
3/31/2023	8	-17	-17	-16	N/A
12/31/2022	9	-15	-15	-15	N/A
9/30/2022	8	-17	-16	-16	N/A
6/30/2022	8	-18	-18	-17	N/A
3/31/2022	8	-19	-18	-17	N/A
12/31/2021	8	-20	-18	-18	N/A
9/30/2021	8	-18	-17	-17	N/A
6/30/2021	8	-17	-17	-17	N/A
3/31/2021	8	-17	-17	-16	N/A
12/31/2020	7	-18	-17	-17	N/A
9/30/2020	7	-19	-17	-17	N/A
6/30/2020	6	-19	-17	-16	N/A
3/31/2020	6	-20	-17	-17	N/A
12/31/2019	6	-23	-17	-16	N/A
9/30/2019	6	-22	-16	-15	N/A
6/30/2019	6	-22	-15	-15	N/A
3/31/2019	5	-22	-15	-14	N/A
12/31/2018	5	-17	-15	-15	N/A
9/30/2018	4	-29	-15	-15	N/A
6/30/2018	4	-27	N/A	-15	N/A
3/31/2018	4	-27	N/A	-15	N/A
12/31/2017	4	-25	N/A	-12	N/A
9/30/2017	3	-14	N/A	-11	N/A
6/30/2017	3	-15	N/A	-13	N/A
3/31/2017	2	-16	N/A	-12	N/A
12/31/2016	1	-18	N/A	-16	N/A
9/30/2016	1	-19	N/A	-18	N/A
6/30/2016	N/A	-22	N/A	-19	N/A
3/31/2016	N/A	-24	N/A	-22	N/A
12/31/2015	0	-27	N/A	-23	N/A
9/30/2015	0	-27	N/A	-24	N/A
6/30/2015	0	-26	N/A	-24	N/A
3/31/2015	0	-26	N/A	-23	N/A
12/31/2014	0	-26	N/A	-23	N/A
9/30/2014	0	-26	N/A	-23	N/A
6/30/2014	0	-26	N/A	-22	N/A
3/31/2014	0	-24	N/A	-20	N/A
12/31/2013	0	-22	N/A	-17	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NUWE önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: NUWE önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: NUWE önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: NUWE şirketinin gelirinin (yıllık 35.8% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: NUWE şirketinin gelirinin (yıllık 35.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NUWE 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Nuwellis Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Nuwellis Provides Revenue Guidance for Third Quarter Ended September 30, 2024

Consensus EPS estimates upgraded to US$2.69 loss

Price target decreased by 36% to US$6.00

Consensus revenue estimates fall by 19%

Price target decreased by 27% to US$16.00

Consensus EPS estimates upgraded to US$13.08 loss

Recent updates

Nuwellis Provides Revenue Guidance for Third Quarter Ended September 30, 2024

Nuwellis, Inc. to Report Q3, 2024 Results on Nov 11, 2024

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Nuwellis, Inc. has completed a Follow-on Equity Offering in the amount of $0.891783 million.

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $0.916782 million.

Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions

Nuwellis Announces First Pediatric Patient Treated in A Commercial Setting with Seastar Medical's Quelimune Therapy At Cincinnati Children's

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $1.990002 million.

Nuwellis, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Nuwellis Marks First Commercial Sale of Quelimune Therapy to Cincinnati Children's

Nuwellis, Inc. Announces New Clinical Evidence Demonstrating the Efficacy of its Aquadex® System to be Presented at HFSA 2024 Conference

Nuwellis Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

Nuwellis, Inc. to Report Q1, 2024 Results on May 07, 2024

Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

Consensus EPS estimates upgraded to US$2.69 loss

Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days

Full year 2023 earnings: EPS exceeds analyst expectations

Nuwellis, Inc. to Report Q4, 2023 Results on Mar 05, 2024

New major risk - Share price stability

Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Nuwellis Receives Non-Compliance Notice from Nasdaq

Nuwellis, Inc. Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring Foriatric Patients

Price target decreased by 36% to US$6.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Less than half of directors are independent

Nuwellis, Inc. Announces Board of Directors Transition

Nuwellis, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Nuwellis, Inc. has completed a Composite Units Offering in the amount of $2.25 million.

Nuwellis Provides Regulatory Update on Seastar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under A Humanitarian Device Exemption

New major risk - Share price stability

Nuwellis, Inc. Appoints Robert B. Scott as Chief Financial Officer, Effective September 2, 2023

Second quarter 2023 earnings released: US$3.65 loss per share (vs US$40.67 loss in 2Q 2022)

Nuwellis, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Revenue and earnings growth

Nuwellis, Inc. Announces the Appointment of Mike Mccormick to its Board of Directors

Consensus revenue estimates fall by 19%

Price target decreased by 27% to US$16.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$13.08 loss

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Nuwellis, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Nuwellis, Inc. Announces Board Changes

Nuwellis, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Nuwellis Appoints John Jefferies as Chief Medical Officer

Nuwellis Announces Compliance with Nasdaq Listing Requirements

Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

Price target decreased to US$2.17

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Nuwellis, Inc. Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using A Modified Aquadex in Low-Birth-Weight Preterm Neonates

Insufficient new directors

Consensus forecasts updated

Nuwellis, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Nuwellis hires Lynn Blake as CFO

Nuwellis, Inc. Provides Product Revenue Guidance for the Three Months Ended September 30, 2022

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality At the 2022 Hfsa Meeting

Insufficient new directors

Nuwellis, Inc. Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial

Nuwellis, Inc. Announces Executive Changes

Nuwellis, Inc. Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

Nuwellis surges 90% on positive data from Postoperative Coronary Artery Bypass Grafting treatment

Nuwellis, Inc. Announces U.S. Patent and Trademark Office Awards Patent for Innovative Pediatric Technology

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Nuwellis Q2 2022 Earnings Preview

Nuwellis, Inc Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA

Nuwellis, Inc. to Report Q2, 2022 Results on Aug 09, 2022